Vol 5, Supplement 6 (November 30, 2016): Translational Cancer Research

Editorial

Glioblastoma radiosensitization by pimozide

Barbara H. Rath, Kevin Camphausen, Philip J. Tofilon

PDF Pages: S1029-S1032 Full Text (2475) COI Form Open Access

MLK4 activates the NF-κB network to drive mesenchymal transition in glioblastoma

Leonie M. Quinn, Ross D. Hannan

PDF Pages: S1033-S1038 Full Text (3111) COI Form Open Access

Mesenchymal stromal cells and interferon α (IFNα) in cancer immunotherapy

Diana Saleiro, Sara G. Radecki, Leonidas C. Platanias

PDF Pages: S1039-S1043 Full Text (4751) COI Form Open Access

Rethinking clinical trial design: maximizing the results from each clinical trial participant

Aaron Etra, Charles L. Shapiro

PDF Pages: S1044-S1046 Full Text (1911) COI Form Open Access

INTEGRATE phase II trial: regorafenib vs. placebo in pretreated metastatic gastric cancer patients—is there anything new?

Marco Puzzoni, Laura Demurtas, Valeria Pusceddu, Mario Scartozzi

PDF Pages: S1047-S1050 Full Text (3317) COI Form Open Access

Hedgehog signaling in colorectal cancer: a spiny issue gets smoothened

Melania Scarpa, Marco Scarpa

PDF Pages: S1051-S1054 Full Text (3695) COI Form Open Access

An ace in the hole for hepatocellular carcinoma: yttrium-90 radioembolization

Giovanni Battista Levi Sandri, Giuseppe Maria Ettorre

PDF Pages: S1055-S1056 Full Text (2034) COI Form Open Access

New insights into the mechanisms of EZH2’s promotion of oncogenesis

David M. Dorfman, Xuejun Tian

PDF Pages: S1057-S1060 Full Text (3588) COI Form Open Access

Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon?

Chiara Ciccarese, Giampaolo Tortora, Rodolfo Montironi, Francesco Massari

PDF Pages: S1061-S1065 Full Text (2970) COI Form Open Access

Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers

Narendra Nath Basu, D. Gareth Evans

PDF Pages: S1066-S1069 Full Text (3955) COI Form Open Access

Determination of the optimal screen interval in low-dose CT lung cancer screening: are we there yet?

Marjolein A. Heuvelmans, Matthijs Oudkerk

PDF Pages: S1070-S1072 Full Text (2335) COI Form Open Access

Prostaglandin E₂ plays a major role in glioma resistance and progression

Lisa Oliver, Christophe Olivier, François M. Vallette

PDF Pages: S1073-S1077 Full Text (4084) COI Form Open Access

Information-dense analysis for information-dense understanding

Nikola A. Ivica, Mandeep Kaur, Guangan Hu, Jianzhu Chen

PDF Pages: S1078-S1081 Full Text (3750) COI Form Open Access

Thriving where others have faltered—a critical appraisal of the role of patient factors versus treatment effect in JCOG0605 trial in relapsed small cell lung cancer

Nikita T. Patel, Taofeek K. Owonikoko

PDF Pages: S1082-S1084 Full Text (2166) COI Form Open Access

The use of malaria glycosaminoglycan to block cancers—lessons from the human placenta

Evdokia Dimitriadis

PDF Pages: S1085-S1087 Full Text (2614) COI Form Open Access

A genomic analysis of large cell neuroendocrine carcinoma versus small cell lung cancer: which is which?

Justine N. McCutcheon, Xiaoliang Zhao, Giuseppe Giaccone

PDF Pages: S1088-S1092 Full Text (3560) COI Form Open Access

Pancreatic cancer cell invasion: mesenchymal switch or just hitchhiking?

Rémi Samain, Christine Jean, Corinne Bousquet

PDF Pages: S1093-S1097 Full Text (2703) COI Form Open Access

Subventricular zone microenvironment protects glioblastoma cells from radiotherapy cytotoxicity: role of the chemokine CXCL12

Roberto Würth, Tullio Florio

PDF Pages: S1098-S1101 Full Text (2298) COI Form Open Access

Sleeve lobectomy or pneumonectomy for non-small cell lung cancer? Searching for an optimal balance between oncological, surgical and functional results

Filippo Lococo, Giacomo Cusumano, Stefano Margaritora, Marco Alifano, Giovanni Leuzzi, Massimiliano Paci

PDF Pages: S1102-S1106 Full Text (2788) COI Form Open Access

The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies

Keith T. Schmidt, William D. Figg

PDF Pages: S1107-S1110 Full Text (8139) COI Form Open Access

The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals

Ming-Lung Yu, Chung-Feng Huang

PDF Pages: S1111-S1115 Full Text (2849) COI Form Open Access

Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy

Roberta Zappasodi, Taha Merghoub

PDF Pages: S1116-S1118 Full Text (3024) COI Form Open Access

Role of adaptive randomization in developing novel therapies for patients with breast cancer

Robert S. Meehan, Alice P. Chen, James H. Doroshow

PDF Pages: S1119-S1122 Full Text (2738) COI Form Open Access

Resistance mechanisms to PD-1 inhibition in melanoma

Raphael Brandao, Patrick A. Ott

PDF Pages: S1123-S1125 Full Text (2337) COI Form Open Access

Advances in molecular genetics of early-stage urothelial carcinoma

Chien-Feng Li, Wen-Jeng Wu, Yow-Ling Shiue

PDF Pages: S1126-S1130 Full Text (2404) COI Form Open Access

Moving from immune phenotyping of colorectal cancer to mechanistic insights on aspirin use

Halei C. Benefield, John A. Baron, Til Stürmer, Melissa A. Troester

PDF Pages: S1131-S1134 Full Text (2421) Open Access

Interplay between MMP-8 and TGF-β1 and its role in regulation of epithelial to mesenchymal transition in hepatocellular carcinoma

Shaoyu Zhou, James E. Klaunig

PDF Pages: S1135-S1138 Full Text (3281) COI Form Open Access

Commentary

Is microRNA expression profile in prostate cancer dependent on clinicopathologic stage or cell subtype?

Karthik V. Giridhar, Manish Kohli, Liang Wang

PDF Pages: S1139-S1141 Full Text (1625) COI Form Open Access

Cisplatin, etoposide, and irinotecan for relapsed small-cell lung cancer

Angel Qin, Gregory P. Kalemkerian

PDF Pages: S1142-S1144 Full Text (4695) COI Form Open Access

Turning the concept of synthetic lethality on its head

Eileen E. Parkes, Richard D. Kennedy

PDF Pages: S1145-S1148 Full Text (3142) Open Access

Dealing with complexity: prognostic implications of karyotype and mutations in chronic lymphocytic leukemia

Nicole R. Grieselhuber, Justin M. Asquith, Leslie A. Andritsos

PDF Pages: S1149-S1152 Full Text (3436) COI Form Open Access

Thoracoscopic surgery for lung cancer without interruption of anti-platelet agents: is it really safe?

Katsuhiro Okuda, Ryoichi Nakanishi

PDF Pages: S1153-S1156 Full Text (2202) COI Form Open Access

Is the ColDx assay a valid prognostic marker for stage II colon cancer?

Jessica Felton, Jean-Pierre Raufman

PDF Pages: S1157-S1159 Full Text (2486) COI Form Open Access

Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better

Ahmad Awada, Nicolas Penel, Nuria Kotecki

PDF Pages: S1160-S1162 Full Text (2875) COI Form Open Access

Identifying ADP-ribosylation targets by chemical genetics

Aswin Mangerich, Matthias Altmeyer

PDF Pages: S1163-S1166 Full Text (4334) COI Form Open Access

Implications of the lymph nodal ratio in resected N1 non-small cell lung cancer

Vivek Verma, Steven H. Lin

PDF Pages: S1167-S1169 Full Text (2061) Open Access

Predicting disease recurrence in stage II colon cancer: expression signatures and other biomarkers

Klaus-Peter Janssen

PDF Pages: S1170-S1172 Full Text (2323) COI Form Open Access

Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer

Sacha I. Rothschild

PDF Pages: S1173-S1176 Full Text (2204) Open Access

Unraveling epigenetic regulation of epithelial mesenchymal transition

Rattiyaporn Kanlaya, Visith Thongboonkerd

PDF Pages: S1177-S1180 Full Text (2697) COI Form Open Access

Biomarker guided treatment of advanced non-small cell lung cancer: does feasibility translate to improvements in patient care?

Abdulaziz Al Farsi, Peter Ellis

PDF Pages: S1181-S1184 Full Text (2361) Open Access

G-protein coupled receptor PAR₁ is overexpressed in glioma progenitor cells

Rachel Bar-Shavit, Jeetendra Kumar Nag, Sorina Grisaru-Granovsky, Beatrice Uziely

PDF Pages: S1185-S1188 Full Text (2836) COI Form Open Access

Xist at the edge: silencing at the nuclear periphery extends to X inactivation

Justin Demmerle, Lothar Schermelleh

PDF Pages: S1189-S1191 Full Text (3027) COI Form Open Access

Genetic and epigenetic alterations in urothelial carcinoma

Hon-Yi Lin, Michael W. Y. Chan

PDF Pages: S1192-S1195 Full Text (2190) COI Form Open Access

Loss of LARP4B, an early event in the tumorigenesis of brain cancer?

Sarah Blagden, Cornelius Schneider, Utz Fischer

PDF Pages: S1196-S1199 Full Text (2677) COI Form Open Access

A vicious cycle of metabolic interaction between leukemia stem cells and adipose tissues: implications in cachexia and drug resistance

Yi-Qing Li, Pan-Pan Liu, Peng Huang

PDF Pages: S1200-S1203 Full Text (2558) COI Form Open Access

miRNA profile as a predictor of response to chemoradiation therapy for esophageal squamous cell carcinoma

Kazuto Harada, Dilsa Mizrak Kaya, Yusuke Shimodaira, Shumei Song, Hideo Baba, Jaffer A. Ajani

PDF Pages: S1204-S1207 Full Text (2606) COI Form Open Access

JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function

Theodoros Karantanos, Vassiliki A. Boussiotis

PDF Pages: S1208-S1211 Full Text (4331) COI Form Open Access

AKT inhibition: a bad AKT inhibitor in liver injury and tumor development?

Anna Joy, Burt Gary Feuerstein

PDF Pages: S1212-S1213 Full Text (3320) COI Form Open Access

Perspective

Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours?

Subotheni Thavaneswaran, Jeremy Shapiro, Eva Segelov

PDF Pages: S1214-S1221 Full Text (3595) COI Form Open Access

Molecular cross-talk between the liver and white adipose tissue links excessive noURIshment to hepatocellular carcinoma

Alexandra A. Roberts, Lionel W. Hebbard

PDF Pages: S1222-S1226 Full Text (4156) COI Form Open Access

Lung cancer screening: screening frequency and lung cancer risk

Renee L. Manser

PDF Pages: S1227-S1232 Full Text (4378) COI Form Open Access

Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer

Nathaniel J. Myall, Heather A. Wakelee

PDF Pages: S1233-S1240 Full Text (3264) COI Form Open Access

Contemporary management of renal angiomyolipomas

Amy Lim, E. Jason Abel

PDF Pages: S1241-S1247 Full Text (11760) COI Form Open Access

MET-inhibitors meet MET mutations in lung cancer

Nagio Takigawa

PDF Pages: S1248-S1254 Full Text (4635) Open Access

Combination chemotherapy for relapsed small-cell lung cancer—perspective on mechanisms of chemoresistance

Gerhard Hamilton, Barbara Rath

PDF Pages: S1255-S1261 Full Text (4025) COI Form Open Access

MicroRNAs as novel elements in personalized radiotherapy

Simone Moertl, Lisa Mutschelknaus, Theresa Heider, Michael J. Atkinson

PDF Pages: S1262-S1269 Full Text (4611) COI Form Open Access

Perspective on targeting salt-inducible kinase 2 (SIK2) in ovarian cancer metastasis

Nathaniel Jensen, Hiu Wing Cheung

PDF Pages: S1270-S1273 Full Text (3057) COI Form Open Access

Protease-activated receptor 1 (PAR1): a promising target for the treatment of glioblastoma?

Vitor Hugo de Almeida, Robson Q. Monteiro

PDF Pages: S1274-S1280 Full Text (4810) COI Form Open Access

Neoadjuvant chemotherapy versus chemoradiation for esophageal cancer: no survival difference does not mean no differences

Jose Mario Pimiento, Sarah E. Hofffe, Khaldoun Almhanna

PDF Pages: S1281-S1283 Full Text (3269) COI Form Open Access

In vivo cancer metabolism is defined by the nutrient microenvironment

Ilaria Elia, Sarah-Maria Fendt

PDF Pages: S1284-S1287 Full Text (7780) COI Form Open Access

The p53 orbit in chronic myeloid leukemia: time to move to patient care

Alessandro Morotti, Giovanna Carrà, Sabrina Crivellaro

PDF Pages: S1288-S1291 Full Text (3555) COI Form Open Access

Correspondence

IL2 based immunotherapies: towards a personalized and curative antitumor response

Nicolle H. Rekers, Veronica Olivo Pimentel, Ala Yaromina, Ludwig Dubois, Philippe Lambin

PDF Pages: S1292-S1294 Full Text (1974) COI Form Open Access

Immunotherapy of pancreatic cancer—weal and woe

Alexandr V. Bazhin, Jens Werner, Svetlana Karakhanova

PDF Pages: S1295-S1296 Full Text (1847) COI Form Open Access

The regulation of cancer cell glutamine metabolism

Michael J. Lukey, Richard A. Cerione

PDF Pages: S1297-S1298 Full Text (2454) COI Form Open Access

Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary

Karen T. Brown, Richard Kinh Do, Mithat Gonen, Anne M. Covey, George I. Getrajdman, Constintinos T. Sofocleous, William R. Jarnagin, Michael I. D’Angelica, Peter J. Allen, Joseph P. Erinjeri, Lynn A. Brody, Stephen B. Solomon, Lawrence H. Schwartz, Ronald P. DeMatteo, Ghassan K. Abou-Alfa

PDF Pages: S1299-S1301 Full Text (2123) COI Form Open Access

Cancer-like mutations in non-cancer tissue: towards a better understanding of multistep carcinogenesis

Jeffrey D. Krimmel, Jesse J. Salk, Rosa Ana Risques

PDF Pages: S1302-S1304 Full Text (2161) Open Access

Targeted attack: mechanisms by which ovarian cancers suppress the immune system

Irina V. Tiper, Tonya J. Webb

PDF Pages: S1305-S1306 Full Text (3327) COI Form Open Access

Disclosure:

This supplement was published without any sponsorship or funding.